Keywords: mixed, data, acorda, fampridine-sr, therapeutics, reported, preliminary
Mixed data for Acorda's Fampridine-SR
Article | 19 April 2004
Acorda Therapeutics has reported preliminary results from a Phase II multiple sclerosis trial of its lead product Fampridine-SR (4-aminopyridine), as ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
